Fixed-combination of rosuvastatin with ezetimibe in the treatment of secondary prevention patient
Authors:
Martina Vaclová; Michal Vrablík
Authors‘ workplace:
Centrum preventivní kardiologie, III. Interní klinika VFN a 1. LF UK v Praze
Published in:
AtheroRev 2018; 3(3): 197-200
Category:
Overview
The case report documents a secondary prevention patients referred to the Centre of preventive cardiology of the GUH in Prague due to persistent elevation of LDL-C levels despite maximum intensity treatment.The case report documents a secondary prevention patients referred to the Centre of preventive cardiology of the GUH in Prague due to persistent elevation of LDL-C levels despite maximum intensity treatment.
Key words:
ezetimibe, LDL-C, PCSK9 inhibitors, secondary prevention, statin, total cholesterol, treatment goals
Received: 14. 9. 2018
Accepted: 1. 10. 2018
Sources
- Vrablik M, Freiberger T, Bláha V et al. [Pracovní skupina České společnosti pro aterosklerózu]. Souhrn konsenzu panelu expertů European Atherosclerosis Society k otázce diagnostiky a klinickému vedení nemocných s familiární hypercholesterolemií. Hypertenze a KV prevence 2015; 4(2): 44–48.
- Tichy L, Fajkusova L, Zapletalova L et al. Molecular Genetic Background of an Autosomal Dominant Hypercholesterolemia in the Czech Republic. Physiol Res 2017; 66(Suppl 1): S47-S54.
- Vrablik M, Piťha J, Bláha V et al. Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2016. AtheroRev 2017; 2(3): 185–193.
- Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165(10): 1147– 1152. Dostupné z DOI: <http://dx.doi.org/10.1001/archinte.165.10.1147>.
- Varbo A, Benn M, Tybjærg-Hansen A et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013; 61(4): 427–436. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2012.08.1026>.
- Vrablik M. Farmakoterapie dyslipidemie. 2. vyd. Maxdorf: Praha 2016. ISBN 978–80–7345–503–3.
- Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun; 129(25 Suppl 2): S1-S45. Dostupné z DOI: <http://dx.doi.org/10.1161/01.cir.0000437738.63853.7a>. Erratum in Correction. [Circulation. 2015]Circulation 2014; 129(25 Suppl 2): S46-S48.
- Vrablík M, Šatný M, Laštůvka J. Ezetimib v léčbě diabetické dyslipidemie. DMEV 2018; 21(2): 71–74.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2018 Issue 3
Most read in this issue
- Fibrates in 2018: story goes on
- Statins, brain and cholesterol: is it going together?
- Anorexia nervosa and lipid metabolism disorders
- Lysosomal storage disorders as the cause of dyslipoproteinemia